icon-folder.gif   Conference Reports for NATAP  
 
  59th Annual Meeting of the American Association
for the Study of Liver Diseases
(AASLD)
Oct 31-Nov 1 2008
San Francisco, CA
Back grey_arrow_rt.gif
 
 
 
Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102)
 
 
  Reported by Jules Levin
59th Annual Meeting of the American Association for the Study of Liver Disease
October 31-November 4, 2008
San Francisco, CA
Oral Presentation # 146
 
Patrick Marcellin1, Maria Buti2, Zahary Krastev3, Selim Gurel4, Rozalina Balabanska5, Geoff Dusheiko6, Robert Myers7, E Jenny Heathcote8, Jeff Sorbel9, Jane Anderson9, Elsa Mondou9 and Franck Rousseau9
 
AUTHOR CONCLUSIONS - Week 96
 
TDF demonstrated durable, potent antiviral activity through Week 96: -- 99% of patients (On-treatment) on therapy had HBV DNA <400 copies/mL (90% ITT)
 
No resistance to TDF monotherapy detected up to 2 years
 
Patients can safely and effectively switch from ADV to TDF treatment:
-- 100% of patients (n-treatment) had HBV DNA <400 copies/mL (89% ITT)
 
TDF was well tolerated through Week 96

Aim-1.gif

teno-2.gif

Charac-3.gif

LAM-4.gif

TDD-5.gif

Breka-6.gif

PT-7.gif

polRT-8.gif

creatine-9.gif